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ABSTRACT  
Objective: Although the underlying cause of Huntington’s disease (HD) is well established, the 
actual pathophysiological processes involved remain to be fully elucidated. In other 
proteinopathies such as Alzheimer’s and Parkinson’s diseases, there is evidence for impairments 
of the cerebral vasculature as well as the blood-brain barrier (BBB), which have been suggested 
to contribute to their pathophysiology. We therefore investigated whether similar changes are 
also present in HD.  
Methods: We used 3- and 7-Tesla magnetic resonance imaging as well as post-mortem tissue 
analyses to assess blood vessel impairments in HD patients. Our findings were further 
investigated in the R6/2 mouse model using in situ cerebral perfusion, histological analysis, 
Western blotting, as well as transmission and scanning electron microscopy. 
Results: We found mutant huntingtin protein (mHtt) aggregates to be present in all major 
components of the neurovascular unit of both R6/2 mice and HD patients. This was accompanied 
by an increase in blood vessel density, a reduction in blood vessel diameter as well as BBB leakage 
in the striatum of R6/2 mice, which correlated with a reduced expression of tight junction-
associated proteins (claudin-5 and occludin) and increased numbers of transcytotic vesicles, 
which occasionally contained mHtt aggregates. Finally, we confirmed the existence of similar 
vascular and BBB changes in HD patients.  
Interpretation: Taken together, our results provide evidence for alterations in the cerebral 
vasculature in HD leading to BBB leakage, both in the R6/2 mouse model and in HD patients, a 
phenomenon that may in turn have potential pathophysiological implications.  
 
Key words: Cerebral vasculature, blood-brain barrier, mutant huntingtin, R6/2, tight junctions, 
vesicles  
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INTRODUCTION 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder that presents 
with a range of motor, cognitive, psychiatric and metabolic abnormalities. The clinical and 
pathological signs of the disease result from an abnormal CAG repeat expansion in exon 1 of the 
huntingtin gene, leading to the expression of the mutant huntingtin (mHtt) protein. This mutated 
huntingtin isoform encodes a polyglutamine stretch that gives rise to oligomers and fibrillary 
structures 1. While the pathogenic effects of aggregate formation are still being debated 3-6, the 
available evidence suggests that the oligomeric form of the protein is the most toxic (for review, 
see 7). 
 
Given the genetic origin of HD, the process of mHtt oligomerization, aggregate formation and 
associated pathology has been believed to be essentially cell-autonomous. However, a number 
of recent studies have challenged this assumption 8,9. In particular, our recent post-mortem 
analysis of HD patients who had been in receipt of fetal striatal allografts has revealed the 
presence of mHtt aggregates within the genetically-unrelated grafted tissue 10. These mHtt 
aggregates were found almost exclusively within the extracellular matrix of the grafted tissue, 
and in cells associated with blood vessels as well as within perivascular macrophages 10. This not 
only provided the first in vivo demonstration of mHtt spread in patients with a monogenic human 
neurodegenerative disorder of the central nervous system (CNS), but also suggested the existence 
of non cell-autonomous mechanisms of pathological protein transmission. These findings, along 
with recent work demonstrating that mHtt is expressed in peripherally circulating monocytes 11, 
raise the intriguing possibility that mHtt might be transported into the CNS via peripheral blood-
borne cells. Despite the fact that the latter cells have limited access to the CNS due to the blood-
brain-barrier (BBB), there is increasing evidence that a number of neurodegenerative disorders 
are associated with alterations in the cerebrovasculature, including the neurovascular unit and 
the BBB 12,13, which may facilitate the access of peripheral cells to the CNS compartment.  
 
In this regard, we and others have recently reported that there are changes in cerebrovascular 
vessel density in HD patients and in transgenic mouse models of the disease 14,15. However, aside 
from a few studies conducted in the 1990s showing reduced cerebral blood flow in the caudate 
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of HD patients secondary to cell loss 16-19, the vascular changes and integrity of the BBB have not 
been systematically investigated despite their obvious clinical and therapeutic relevance. We now 
present the first extensive study in both the R6/2 transgenic mouse model and patients with HD 
investigating mHtt expression in cells associated with blood vessels, as well as its impact on 
vascular changes and BBB permeability.   
 
MATERIALS AND METHODS  
 
Human studies 
Participants 
HD patients and age- and sex-matched control subjects were recruited from the HD clinic at the 
John van Geest Centre for Brain Repair (Cambridge, UK) (Table 1). None of the subjects had a 
history of vascular disease. Participants provided informed consent, and procedures were 
conducted under the Research Ethics Committee approval (REC 12/EE/0528). Burden of disease 
score was calculated as described 20. 
 
3T MRI  
Subjects were scanned using a 3T Siemens TimTrio system. Structural imaging was achieved with 
an MPRAGE acquisition (TR/TI/TE: 2300/900/3 ms; FOV: 25.6×24.0×17.6mm3; matrix 
256×240×176). DCE imaging based on a 3D-FLASH sequence used TR/TE, 3.5/1.4ms; FOV 
230×230×85 mm3; matrix 128×128×17; 25% zero-filling and two-fold acceleration for 6s temporal 
resolution. To measure T1, images (flip angles (FA) from 5 to 35°) were acquired. The dynamic 
series consisted of 120 frames (FA 25°) acquired over 12 minutes,  gadobutrol (9 ml; 1.0 mmol/ml 
Gd-DTPA; Bayer) was injected into the medial cubital vein at 5 ml/s followed by a saline flush of 
20 ml. Structural images were corrected for inhomogeneity, registered to a template (Montreal 
Neurological Institute) and segmented into gray matter, white matter and cerebrospinal fluid 
portions using Statistical Parametric Mapping 12 (SPM12) (Wellcome Trust Centre for 
Neuroimaging). The Parker arterial input function 21 was used to fit permeability (Ktrans) and 
voxelwise vessel fraction using Patlak analysis 22. Statistical parametric mapping (SPM) was used 
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to produce voxelwise statistical parametric maps for Ktrans group differences between patients 
and controls, masked using segmented grey and white matter maps. Type I errors due to multiple 
comparisons were controlled using family-wise error correction.. Hand-drawn regions of interests 
(ROIs) for the caudate and putamen were used to extract mean values. ROIs were produced using 
Analyze 12 (Mayo Clinic) and calculated permeability maps were transformed to match the 
higher-resolution structural MRI space using SPM12. Within each ROI, outlying values were 
excluded by taking the mean of values within the 1-99% percentiles. 
 
7T MRI  
Subjects were scanned on a 7T Philips Achieva system with head transmit and 32-channel receive 
coil, using image-based shimming to correct for field inhomogeneities. A Look-Locker echo-planar 
imaging (LL-EPI), flow-sensitive alternating inversion recovery (FAIR) arterial spin labeling (ASL) 
protocol23-25 was used to generate arterial cerebral blood volume (aCBV) maps. Acquisition 
parameters: 21 LL-EPI readout pulses per 4.8 s label/control pair; GE-EPI readout (FA 55o; TE 10 
ms; FOV 216 mm x 192 mm and 2 mm in-plane resolution; slice thickness 4 mm); in-plane 
saturation; initial delay 150 ms, LL-EPI readout spacing 100 ms; 15/230 mm selective/non-
selective inversion; 20 averages. For coverage of caudate/putamen/cortical gray matter, aCBV 
acquisitions were collected at 3 slice locations parallel to the AC-PC line (centered on the caudate 
and putamen, and 10 and 20 mm above). A base magnetization image was collected to estimate 
M0blood for aCBV quantification, and inversion-recovery images to form a T1 map. A 0.8 mm 
isotropic phase-sensitive inversion recovery (PSIR) anatomical image was acquired to define ROIs 
and assess atrophy. A Turbo Field EPI was used to generate magnetic resonance angiograms 
(MRA) (EPI factor 3; TR/TE 19.12/10.34 ms; FA 7°; voxel size 0.6 mm isotropic; matrix 384 x 384 x 
100). Caudate and putamen ROIs were defined from the PSIR scan, and a cortical gray matter ROI 
was formed by thresholding the T1 map at 1.7 ≤ T1 ≤ 2.3 s. Average aCBV (ml blood/100 ml tissue) 
and arterial transit time (s) within each ROI was calculated using a two-compartment vascular 
kinetic model as described in23,25.   
 
Post-mortem human brain tissue 
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Post-mortem human brain tissue was obtained from the Cambridge Brain Bank and used under 
local ethical approval (REC 01/177). The severity of HD was graded by a certified pathologist 
according to the Vonsattel grading system 26,27. All post-mortem analyses conducted in Canada 
were approved by the Comité d'éthique de la recherche du CHU de Québec (#A13-02-1138). The 
CAG repeat size in the HTT gene was determined for each HD case by DNA sequencing (Sanger 
Sequencing Services; Laragen Inc.) (see Suppl Table 1 for details on the sample used).  
 
Immunofluorescence imaging of human tissue  
Paraffin-embedded sections were stained as described {Arsenault et al., 2015, #94413}. For 
confocal microscopy, tissue preparation and immunofluorescent staining, procedures were 
performed as described 10,14. Images were acquired using the simultaneous 
confocal/multichannel fluorescence mode of the TISSUEscope™ digital slide scanner (Huron 
Digital Pathology). Whole brain sections were digitized using magnification ≤ 40X. The confocal 
optical slices were merged into a reconstructed volume using software available from Huron 
Digital Pathology. Sections were imaged with a Fluoview FV1000 confocal microscope system 
equipped with 559-nm and 635-nm laser diodes and an Ar 488-nm laser (Olympus Canada Inc.). 
For the quantification of the percentage of vWF+ and laminin+ blood vessels expressing EM48+ 
aggregates, m = 627 and m = 173 were assessed in 8 and 6 fields of view, respectively. Diameter 
of blood vessels assessed ranged from 5 to 94 µm. 
 
Blood vessel density, morphometric and extravasation analyses 
Images of the entire putamen were taken at 2000-µm intervals using Stereo Investigator software 
(MBF Bioscience) integrated with an E800 Nikon microscope (Nikon Canada) using an automated 
platform. Analyses were performed using ImageJ (National Institutes of Health, 
http://imagej.nih.gov/ij). For blood vessel leakage analysis, masks from collagen IV and fibrin 
were obtained and assigned to a color (magenta for blood vessels and yellow for albumin). After 
merging images, magenta and white (from the colocalization of magenta and yellow) were 
removed, leaving only the fibrin staining (yellow) (cf. Fig. 6B).  
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Western blot analysis and multiplex angiogenesis ELISA assay of human tissues 
Approximately 100 mg of frozen samples of putamen from HD patients andmatched healthy 
controls (Suppl. Table 1) were processed to extract proteins for western blotting according to 
previously published protocols {Drouin-Ouellet et al., 2014, #31993}. For the multiplex assay, 
samples were simultaneously analyzed for 9 human markers associated with angiogenesis and 
BBB permeability, using a Q-Plex™ Human Angiogenesis assay (Quansys Bioscience), according to 
the manufacturer’s instructions.  
 
Animal study 
Animals 
R6/2 mice 31 were purchased from Jackson Laboratory (Bar Harbor) and bred in the John van 
Geest Centre for Brain Repair animal facility (Cambridge, UK). Tissue from ear biopsies was sent 
to Laragen Inc. for genotyping. All mice were housed in a temperature-controlled (22°C) room 
under standard diurnal conditions (12-h light/dark cycle). Food and water were provided ad 
libitum. Animal handling, testing, and other procedures were carried out in the UK in accordance 
with the UK Animals (Scientific Procedures) Act 1986, and with the appropriate Home Office 
Personal and Project Licenses. Animal handling, testing, and other procedures carried out in 
Canada were in accordance with the Canadian Guide for the Care and Use of Laboratory Animals 
and were approved by the Institutional Policy of the Centre de recherche du CHU de Québec 
(CHUQ). For all experiments, 11-15 weeks old R6/2 were used. 
 
In situ cerebral perfusion  
In situ cerebral perfusion was performed using established protocols 32,33. To measure the volume 
and the surface of the vascular network, each mouse was perfused for 240 s with [14C]sucrose 
(0.6 µCi/ml of perfusion buffer; 412 mCi∙mmol-1; Moravek Biochemicals), a vascular space marker 
that does not cross the BBB, and [3H]diazepam (0.3 µCi/ml of perfusion buffer; 83.7 Ci∙mmol-1; 
Perkin Elmer), a highly lipophilic drug that readily crosses the BBB in a flow-limited fashion. The 
right striatum was dissected and the left hemisphere was post-fixed for 48 h in 4% PFA, and 
cryoprotected in 20% (w/v) sucrose for the analysis of blood vessel density and morphometrics. 
The calculations of vascular volumes were performed as described previously 33,34. 
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Mouse tissue preparation and immunofluorescence  
Mouse brains were collected, sliced and free-floating sections were stained as previously 
described {Drouin-Ouellet et al., 2014, #31993} (See Table 2 for antibody list). For the 
lectin/albumin double labeling, DyLight 594-conjugated lectin (Vector Laboratories, 1:100) was 
used. Sections were observed as described above (cf. Immunofluorescence imaging of human 
tissue)  
 
Blood vessel density, morphometric and extravasation analyses 
Three striatal sections per mice, 250 µm apart, were selected, and a 20X magnification image was 
taken in each quadrant of the striatum. Extravasation analysis of albumin was performed as 
described for fibrin in the human study. Analyses were performed using ImageJ. 
 
Brain perfusion and vascular casting for scanning electron microscopy 
Mice were perfused first with 0.9% saline, followed by 100% ethanol. LR White Accelerator 
wasadded to LR White Embedding Medium (Electron Microscopy Science), and mice were 
immediately perfused using this mixture. Tissue was incubated overnight at 37°C and the striatum 
was dissected and soaked in a 4 M KOH solution for 4 weeks. Cast samples were then mounted 
onto a metallic support and observed with a scanning electron microscope JEOL 6360LV set at 30 
kV. 
 
Transmission electron microscopy tissue preparation and analyses 
Mice were subjected to intracardiac perfusion under deep anesthesia first with 0.1 M sodium 
cacodylate, and then with 2.5% glutaraldehyde and 2% PFA and tissue was prepared as described 
(REF Richard; Jeremy?). Observations were performed using a Tecnai G2 Spirit Biotwin electron 
microscope (FEI) set at a 80-kV acceleration voltage. Mesures of tight junction (TJ) were 
performed on 39 to 47 TJs per animal. The portion of the endothelium circumference covered by 
pericytes was measured on 18 to 20 blood vessels per animal. Density of various types of vesicles 
were quantified according to previously published descriptions 36 on 20 vessels per animal. Blood 
vessel subtypes (capillaries or venules) were assigned as described (REF). All analyses were 
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performed using the ImageJ software.  
 
Immunoelectron microscopy 
Mice were perfused with 4% PFA in 0.1 M sodium cacodylate and brains were fixed in the same 
solution before being prepared for immunogold labeling, which was done as described (REF) using 
the EM48 primary antibody and labeled with 10 nm colloidal gold-conjugated anti-mouse 
antibody (BBInternational, 1:100).  
 
Real-time quantitative PCR analysis of mouse tissue  
RNA was extracted from striatal tissue using RNeasy Lipid Tissue Mini Kit (Qiagen). The following 
primer sequences were used: PDGF forward, TGACCCCTCGGCCTGTGACT; PDGF reverse, 5’-
CCGGCGGATTCTCACCGTCC-3’ and the house-keeping gene GAPDH forward, 5’-
GTATGTCGTGGAGTCTACTG-3’, GAPDH reverse, 5’-GAGTTGTCATATTTCTCGTGGT-3’. The qPCR 
was performed using Brilliant III SYBR® Green QPCR Master Mix (Agilent Technologies, Inc) and a 
Mx3005P qPCR system (Stratagene). Relative gene level differences between groups were 
evaluated with the Ct method.  
 
Western blot analysis for mouse tissue 
Striatal tissue (20 mg) was homogenized and Western blot experiments were carried out and 
quantified as described for human tissues.  
 
Statistical analysis 
For studies involving human tissue samples, the pathological grade was taken into account in all 
initial statistical analyses but given that no significant effect was detected, data from HD cases 
were pooled and compared to control subjects. Statistical significance was set at p<0.05. All 
statistical analyses were performed using Prism 6.0, SPSS Statistics version 22 and SAS (version 
9.2, SAS). The Service de Consultation Statistique of Université Laval was consulted for some 
statistical analyses regarding the MRI studies.  
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RESULTS 
Expression of mHtt pathology in cerebral blood vessels  
Building on our previous observation that mHtt aggregates were found in the basal membrane of 
cerebral blood vessels of HD patients 10, we first assessed the expression of mHtt aggregates in 
all compartments of the neurovascular unit. mHtt aggregates were observed inside the basal 
membrane sheaths as well as in the nuclei of cells embedded in the basal membrane in both 
small- (5-10 µm) and large-calibre (>20 µm) blood vessels (Fig. 1A to C). mHtt aggregates were 
found to colocalize with vWF-labelled endothelial cells (Fig. 1D to G), as well as -SMA+ cells 
within the basal membrane (Fig. 1H) and CD163+ perivascular macrophages (Fig. 1I). EM48+ 
aggregates were found in the basal membrane and endothelium of 3 and 7% of cortical blood 
vessels, respectively. Similar to our observations in post-mortem samples from HD cases, EM48+ 
aggregates could also be found both in the basal membrane and inside cells that were embedded 
in the basal membrane of small and larger blood vessels in R6/2 mice, specifically within -SMA+ 
pericytes or smooth muscle cells (Fig. 2A to D), as well as within CD31+ endothelial cells (Fig. 2E).  
 
Vascular changes in the putamen of HD patients  
Given that mHtt can impair mitochondrial integrity and elicit oxidative stress, which may affect 
the physiology of cells composing the cerebral vasculature 37,38, we next investigated 
morphological, structural and functional changes in blood vessels in the context of HD using MRI 
and post-mortem HD tissue. There was a significant increase in aCBV in cortical gray matter in the 
HD cohort (p < 0.05; Fig. 3A), but not in the putamen nor caudate, and the aCBV did not correlate 
with gray matter volume (data not shown). No significant difference was found in arterial transit 
time between HD and control participants (Fig. 3B, C). Qualitative assessment of 7T MRA of 
patients did not yield overt differences in blood vessel density for large-calibre blood vessels (> 
600 µm), although it was not possible to perform proper quantifications given the limited number 
of collected angiograms (Fig. 3D). We thus used post-mortem tissue samples to specifically assess 
potential morphological differences in blood vessels of the putamen of HD patients. 
Measurements of cerebral blood vessel density revealed an increase in HD subjects (p < 0.001; 
Fig. 4A, B), independent of putaminal atrophy (R2 = 0.11; p = 0.15; Fig. 4C). We found no difference 
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in the diameter of small- or medium-sized blood vessels (5-10 µm and 10-20 µm diameter, 
respectively) between HD and matched controls (Fig. 4D), nor in the Feret diameter (data not 
shown). However, we found an increased proportion of small blood vessels (5-10 µm) as 
compared to medium-sized blood vessels (10-20 µm) in the putamen of HD patients (p < 0.01; 
Fig. 4E). Interestingly, a significant positive correlation was found between the size of blood 
vessels and the surface area of the putamen (R2 = 0.37; p < 0.01; Fig. 4F) as well as between the 
Feret diameter and the surface area of the putamen (R2 = 0.26; p < 0.05; Fig. 4G), suggesting that 
putaminal atrophy was accompanied by a reduction in blood vessel size. Finally, we measured the 
wall thickness of the basal membrane, given that this is among the characteristic features of 
vascular pathology in other neurodegenerative diseases such as Alzheimer, but did not detect any 
differences (Fig. 4H). Overall, although the morphology of large-calibre blood vessels remains 
intact in the brain of HD patients, there is an increase in the number of small blood vessels, an 
effect that appears to occur concurrently with putaminal degeneration. 
 
Morphological changes in striatal blood vessels of R6/2 mice  
Given the similar pattern of expression of mHtt aggregates within the neurovascular units of the 
R6/2 mouse and HD patients, we further used the R6/2 mouse to investigate blood vessel 
changes. In line with our observations in human post-mortem samples, the density of striatal 
blood vessels in R6/2 mice was increased (p < 0.01; Fig. 5A, B). This was accompanied by a 
reduction in the average Feret diameter of blood vessels (p < 0.05; Fig. 5C), although apparent 
differences in size vanished upon distinguishing arterioles from capillaries and venules (Fig. 5D), 
suggesting that the decrease in Feret diameter of blood vessels in R6/2 mice is not specific to 
particular blood vessel subtype(s). Scanning electron microscopy revealed further abnormalities 
in the striatal vascular network. Indeed, the vascular network of R6/2 mice was characterized by 
a smaller ratio of the diameter of branches to that of the parent vessel, compared to WT 
littermates (p < 0.05; Fig. 5E, F). Furthermore, several aborted branch buds were observed in the 
striatum of the R6/2, but not of WT littermates (Fig. 5E). We next assessed whether these 
structural changes had an impact on the volume of the striatal vascular network, using in situ 
cerebral perfusion, and found that the Vvasc of the striatal network in R6/2 mice and WT 
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littermates was similar. In agreement with this, brain uptake clearance (Clup) of [3H]diazepam, 
which measures the surface area of the vascular network, was also similar in R6/2 mice and 
controls (Fig. 5G). This data thus supports the scanning electron microscopy and 
immunofluorescence data, showing that the brain vasculature anomalies were restricted to 
smaller vessels.  
 
BBB leakage in HD patients  
We next assessed whether the observed morphological and structural changes in cerebral blood 
vessels of HD patients are associated with functional impairments of the BBB. Decreases in 
expression of proteins forming the TJs of the BBB, such as claudin-5 and occluding, have been 
associated with increased permeability 39. Western blot analysis revealed a significant decrease 
in both proteins (p < 0.01 and p < 0.05, respectively) in the putamen of HD patients (Fig. 6A). 
While we did not detect a significant change in VEGF expression, a significant increase in other 
markers associated with increased BBB permeability such as PDGF(p < 0.05)HGF (p < 0.001), 
IL-8 (p < 0.05), TIMP1 (p < 0.05) and TIMP2 (p < 0.05; Fig. 6D) was observed. To confirm that BBB 
breakdown occurred in the putamen of HD patients, we next measured the levels of extravascular 
fibrin deposition 29,40 and found it to be increased 2.5-fold when compared to controls (p < 0.05; 
Fig. 6B, C). Finally, we assessed whether BBB leakage might be detected in mild-to-moderate 
stage HD patients using a dynamic contrast-enhanced MRI method. Overall, we found a trend 
towards an increased leakage in the caudate and putamen of HD patients as compared to age- 
and sex-matched control subjects (Fig. 7A, B). Interestingly, BBB leakage in the right caudate 
significantly correlated with the burden of disease score (R2 = 0.69; p < 0.05; Fig. 7C), suggesting 
that BBB permeability increases with disease progression in HD. 
 
Paracellular and transcytotic alterations in the striatum of R6/2 mice 
We further characterized paracellular transport and transcytosis across the BBB in R6/2 mice. 
While TJ length in the striatum of R6/2 mice and WT mice was similar, the extracellular cleft on 
the side of the lumen was wider in the transgenic animals (p < 0.05, Fig. 8A). Additionally, TJs had 
a wider angle with respect to the lumen in R6/2 mice (p < 0.05, Fig. 8B, C), suggesting a random 
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junctional alignment in the HD model 41. Moreover, claudin-5 and occludin were both significantly 
decreased in R6/2 mice (p < 0.05; Fig. 8D). Finally, given that TJs may facilitate leukocyte 
diapedesis through weakened inter-endothelial contact points 42, we looked for the presence of 
perivascular cells and found an increased number of CD45+ leukocytes attached to the blood 
vessel walls in R6/2 (Fig. 8E).  
 
In addition to the paracellular barrier formed by the TJs, the BBB provides a transcellular 
hindrance 43. We thus assessed transcytosis in R6/2 mice and found an increase in the total 
number of vesicles in the endothelium of striatal blood vessels (p < 0.05; Fig. 9A) 36. Upon 
assessing the different subtypes of vesicles, we found a 5-fold increase in luminal type II vesicles 
- connected vesicles pinching from the luminal plasma membrane - suggesting an increase in 
pinocytotic events (p < 0.05; Fig. 9B, C). Immunogold labeling of EM48 also revealed the presence 
of gold particles in the endothelium of R6/2 mice, which were further detected within all the 
different subtypes of vesicles (Fig. 9D). In accordance with increased transcytosis in the striatum 
of R6/2 mice, we found a nearly 20-fold increase in extravascular albumin in transgenic mice (p < 
0.05; Fig. 9E), suggesting a disruption of BBB integrity 44. Because pericytes play an important role 
in BBB integrity and since pericyte-deficient mice (pdgfrb-/- mice) display increased transcytosis 
41, we further assessed pericyte coverage, but did not find significant differences (Fig. 9F). 
However, mRNA expression of PDGF was significantly decreased (p < 0.01; Fig. 9G). Taken 
together, these findings suggest an increased BBB permeability in R6/2 mice, which includes 
increased transcytosis and paracellullar transport. 
 
DISCUSSION 
Our data provide clear evidence for ultrastructural, morphological and functional changes in 
cerebral blood vessels with alterations of the BBB in HD, as evidenced both in an animal model of 
disease, the R6/2 mouse, and in humans as shown by MRI in mild-to-moderate stage HD patients 
as well as in post-mortem tissue. 
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In this study, among different blood vessel compartments, we specifically detected the expression 
of mHtt aggregates in endothelial cells, in cells enclosed in the basal membrane, as well as in 
perivascular macrophages 10 (Fig. 10). Ideally, it would be informative to ascertain whether the 
more toxic oligomers are preferentially associated with the latter sites of mHtt aggregate 
accumulation, but given that no antibodies recognizing mHtt oligomers are currently available, 
we were unable to verify this. Nevertheless, the presence of aggregates suggests that such toxic 
species of mHtt are likely to be present in these compartments.  
 
While the specific pathophysiological effects of mHtt expression within these neurovascular 
compartments are yet unknown, neural activity has been shown to affect vascular structure 45-47. 
Therefore, it is possible that the changes reported here are secondary to the effects of mHtt on 
neural activity, although this seems unlikely given the extent of changes observed 48-50. In 
addition, brain endothelial cells contain large numbers of mitochondria as compared to 
peripheral endothelium, and are thus more susceptible to oxidative stress 37,38, which has been 
proposed as an effector of BBB damage and endothelial dysfunction through alterations in the 
expression of TJ-associated proteins 51. An intrinsic dysfunction of endothelial cells secondary to 
their accumulation of mHtt is thus more likely to be the main determinant of the morphological 
and functional changes observed in our study. We have recently shown that allografts of normal 
tissue are not well vascularized in the brain of HD patients 14, which could reflect an intrinsic 
limitation of the cerebral blood vessels in HD in the remodeling and proper vascularization of new 
tissue. Moreover, mHtt is also expressed in astrocytes, and it has been reported mHtt expression 
in this cell type could mediate signs of neurological impairments associated with HD 8. Given that 
astrocytes are an important component of the BBB, the expression of mHtt in these cells could 
also participate in the vascular impairments that occur in HD.  
 
The finding that the size of blood vessels decreases concomitantly with the atrophy of the 
putamen is surprising but might be a consequence of the increased number of smaller blood 
vessels observed here, along with the decrease in the number of arteries. Oxygen diffusion is 
different in arterioles, venules and capillaries, with most oxygen diffusion taking place across the 
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capillary bed 52. An increase in the total surface of capillary beds could help maintain proper 
oxygenation of the surrounding tissues despite a decrease in the number of larger blood vessels. 
This hypothesis may hold provided that the increase in capillary surface compensates for the 
reduced primary blood flow and dissolved oxygen flow rate that results from the decreased 
number of large vessels. Alternatively, a reduced rate of oxygen delivery across a compromised 
vascular network in HD might be the primary event that triggers a compensatory, secondary 
increase in vasculature. Furthermore, aCBV - which in essence measures the volume of blood in 
the arterial, non-capillary, component - was increased in the gray matter of HD patients, in line 
with previous observations in R6/2 mice 15,53. However, the R6/2 mouse model is not 
characterized by overt neuronal death 31, which argues against a direct involvement of neuronal 
loss in the various changes in the vasculature, as does the fact that the increase in density and 
the decrease in the size of blood vessels have been previously reported to develop as early as 5 
to 7 weeks of age in these mice 15. Overall, the available evidence supports the existence of a 
vascular pathology in HD that is independent from the neuronal loss characteristic of the disease. 
 
The HD-associated abnormalities in the vasculature reported here also have functional 
consequences in that the BBB is compromised in both R6/2 mice and HD patients, as we show 
here for the first time. Two previous studies using DCE-MRI in R6/2 mice with Gd-DTPA as a 
contrast agent had failed to show any BBB leakage 15,53. However, the sensitivity of this method 
in small animals is lower and may thus not afford detection of subtle changes in BBB permeability. 
In contrast, our study now shows that in HD patients (using the same contrast agent), there is a 
trend towards an increased permeability of the BBB – i.e. a loss of BBB integrity – with a 
concomitant increase in the burden of disease score. The reason why only a trend could be 
definitively established probably relates to the small sample size (n=7) and the fact that we 
restricted our selection of participants to mild-to-moderate stage HD to avoid issues related to 
movement-dependent artefacts in the scanner secondary to their chorea. However, the 
significance of this trend is reinforced by our post-mortem analyses which revealed unequivocal 
signs of BBB leakage both in R6/2 mice and HD patients, including wider TJ intercellular clefts, 
decreased expression of BBB TJ proteins, increases in perivascular leukocytes, as well as leakage 
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of albumin and fibrin into the brain parenchyma 54-57.  
 
We specifically examined the expression of claudin-5 and occludin, as they are the two major 
proteins associated with BBB TJs. Claudin-5 is a major functional constituent and a critical 
determinant of BBB paracellular permeability in mice by creating size- (< 800 Da) and charge-
selective hydrophilic paracellular pores 58-60, while occludin enhances TJ tightness. Our finding of 
decreases in the expression of these TJ proteins in both R6/2 mice and the HD putamen, along 
with the increase found here in the number of leukocytes in the perivascular space of cerebral 
blood vessels, are likely to reflect an increase in circulating blood cells transiting into the brain of 
HD patients. Moreover, the extravascular accumulation of albumin in the R6/2 brain suggests an 
increase in transcytosis as this protein can be transported through the endothelium via 
transcytostic vesicles, although increased paracellular transport might also contribute to the 
process 61.  
 
The extravascular accumulation of fibrin deposition that we observed in HD brains might be in 
accordance with this hypothesis, as it is a well-known marker of BBB leakage in human autopsy 
tissues 54,56,57. The BBB is vital for protecting the CNS from systemic perturbations and from 
elements of the peripheral immune system, so that any impairment of its integrity could have far-
reaching consequences on the health of the CNS. Thus, our data demonstrating that the integrity 
of the BBB is compromised and that the cerebral vasculature is considerably disrupted in HD, 
likely indicate that these impairments may contribute in driving the disease process. Indeed, this 
data provides evidence linking the well-described peripheral immune changes of HD to the CNS 
pathology 62,63. In particular, the changes reported herein in both mice and human could allow 
peripheral blood leukocytes to enter the CNS more easily, where they might act as vehicles for 
mHtt transfer into the brain, or exacerbate neuronal death by participating in the cerebral 
inflammatory response. The detection of mHtt in transcytotic vesicles, in conjunction with the 
increased transcytosis observed in R6/2 mice, suggests that an exchange of mHtt between the 
blood and the brain is possible – which has obvious implications for HD pathogenesis (Fig. 10).  
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In summary, the clinical and pre-clinical data reported here reveals that mHtt is expressed in 
various cells associated with cerebral blood vessels, which is likely to contribute to the structural 
and functional changes that we find in the BBB. These changes may be important pathogenic 
players allowing a greater access of both mHtt and immune cells to the diseased CNS than 
previously recognized. Overall, the present study not only reveals a new pathogenic process 
underlying HD but also uncovers novel, potentially important therapeutic avenues. 
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FIGURE LEGENDS 
Table 1. Demographic details of the participants involved in the MRI studies. Abbreviations: MRI: 
magnetic resonance imaging; nk: not known; T: Tesla; TFC: total functional capacity; UHDRS: 
Unified Huntington’s disease rating scale. 
 
Table 2. List of the primary antibodies used in the study. Abbreviations: IF: immunofluorescence; 
IG: immunogold; WB: western blot. 
 
Suppl Table 1. Demographic details of the post-mortem brain sample cases. Abbreviations: CTL: 
controls; HD: Huntington’s Disease; nk: not known; PM: post-mortem; SD: standard deviation. 
 
Figure 1. Localization of mHtt aggregates within the blood vessels of HD patients. (A to C) EM48+ 
mHtt aggregates (green) were found within the laminin+ basal membrane (red) and in the nuclei 
of cells lodged within the basal membrane, both in large-calibre (A, A’, B, B’) and small blood 
vessels (C, C’). (D-G) EM48+ mHtt aggregates (green) were found inside the neurovascular unit, 
in vWF+ endothelial cells (red in D to G), SMA+ vascular smooth muscle cells (red in H) and in 
CD163+ perivascular macrophages (gray in H). Abbreviations: -SMA: alpha-smooth muscle actin; 
DAPI: 4’, 6-diamidino-2-phenylindole; vWF: von Willbrand factor. Scale bars A, B, C = 50 µm; A’, 
B’ = 10 µm; C’ = 20 µm; D, E, F = 10 µm; G, H, I = 15 µm.  
 
Figure 2. Localization of mHtt aggregates within blood vessels of R6/2 mice. (A to D) EM48+ 
mHtt aggregates (green) were found within the laminin+ basal membrane (A, B: gray; C, D: blue) 
and cells embedded in it, including SMA+ cells (red). More specifically, mHtt aggregates were 
found within the nucleus (DAPI, A, B: blue; C, D: gray) of cell types associated with blood vessels. 
(E) Immunofluorescent labeling of EM48 (red) also revealed the co-localization of mHtt+ 
aggregates within small blood vessels labeled with the endothelial marker CD31 (green). 
Abbreviations: -SMA: alpha-smooth muscle actin; DAPI: 4’, 6-diamidino-2-phenylindole. Scale 
bars A, B = 30 µm; C, D = 25 µm; E = 50 µm; E’,E” = 25 µm.  
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Figure 3. Morphological changes in blood vessels in mild-to-moderate stage HD patients. (A-C) 
aCBV and (A) arterial transit time (B) quantifications (n=8 HD; n=7 CTL) as well as maps (C) of a 
representative HD subject for each of the 3 slices acquired. Scale in (C) represent the amount of 
ml blood/ml tissue. The caudate nucleus ROI is delineated in blue and the putamen ROI in green. 
(D) Brain angiograms, as acquired using 7T MRI of a representative HD patient and a matched 
control. Data are expressed as means ± SEM. Statistical analysis was performed using a paired 
Student’s t-test. * p<0.05 as compared to controls. Abbreviations: Ant: anterior; CTL: controls; L: 
left; HD: Huntington’s disease; Post: posterior; R: right. 
 
Figure 4. Morphological changes in blood vessels in post-mortem brain samples of HD patients. 
(A) Increase in blood vessel density in the HD putamen (n=24) as compared to controls (n=9). (B) 
Collagen IV immunofluorescent staining (green) revealed an increase in the density of blood 
vessels in the putamen of an HD case, as well as the matching black-and-white masks used for 
blood vessel measurements. (C) Positive correlation of blood vessel density and putaminal 
atrophy in HD patients. (D) Quantification of the blood vessel diameter of small- and medium-
sized blood vessels did not reveal any differences in diameter, but uncovered an increase in the 
proportion of small blood vessels (5-10 µm) and a decrease in the proportion of larger-calibre 
blood vessels (10-20 µm) in the HD putamen (E). Average size (F) and average Feret diameter (G) 
positively correlate with the surface area of the putamen. (H) Wall thickness of small (5-10 µm) 
and larger-calibre blood vessels (10-20 µm) does not differ from controls. Data are expressed as 
Means ± SEM. Statistical analysis was performed using an ANCOVA with age and gender as 
covariates followed by a Bonferroni post-hoc test. Coefficients of correlation were determined 
using the Pearson’s correlation test. * p<0.05, ** p<0.01 vs. controls. Abbreviations: CTL: controls; 
L: left; HD: Huntington’s disease. Scale bar B = 100 µm. 
 
Figure 5. Morphological changes in striatal blood vessels of R6/2 mice. (A) Increase in blood 
vessel density in the striatum of 12-week old R6/2 mice (n=9) as compared to WT littermates 
(n=9). (B) Striatal collagen IV immunofluorescent staining (green) depicting an increase in density 
of blood vessels in the striatum of R6/2 mice as well as the matching black-and-white masks used 
Drouin-Ouellet et al., 2015  
 25 
for blood vessel measurements. (C) Quantification of the average size of striatal blood vessels 
revealed a decrease in R6/2 mice (n=9) as compared to WT littermates (n=9). (D) No difference 
was observed in the size of arterioles nor capillaries-venules in R6/2 mice (n=6) as compared to 
WT littermates (n=6). (E, F) Scanning electron microscopy depicting decreases in the size of blood 
vessel branching (white arrowheads) and presence of unformed, blind-ending branches (blue 
arrowhead) in the striatum of R6/2 mice. (G) Quantification of striatal vascular network volume 
and vascular network surface area using in situ cerebral perfusion with [14C]sucrose and 
[3H]diazepam did not detect differences between WT (n=9) and R6/2 mice (n=9). Data are 
expressed as means ± SEM. Statistical analysis was performed using an unpaired Student’s t-test, 
with application of a Welch correction in cases of unequal variances. * p<0.05, ** p<0.01 vs. 
controls. Abbreviations: WT: wild type. Scale bars B = 100 µm; E = 25 µm, except bottom left 
image = 100 µm. 
 
Figure 6. Post-mortem evidence of BBB disruption in HD patients. (A) Western blot 
measurements of the TJ proteins claudin-5 and occludin revealed a significant decrease of both 
proteins in the putamen of HD patients (n=24) as compared to controls (n=13). (B) Method used 
for the quantification of the extravascular fibrin staining. A yellow mask of the fibrinogen staining 
and a magenta mask of the collagen IV staining were generated using Image J and merged using 
Adobe Photoshop. The magenta and white (from merging magenta and yellow) were then 
deleted, leaving only the extravascular fibrinogen staining (yellow), the surface area of which was 
quantified for each sample using image J. (C) Quantification of the extravascular fibrin positive 
staining shows an increase in fibrin levels outside the blood vessels in the putamen of HD patients 
(n=8) compared to controls (n=5). (D) Expression of protein markers associated with increased 
BBB permeability and angiogenesis was assessed using a multiplex ELISA assay in the human 
putamen of HD patients (n=24) and matched controls (n=14). Statistical analyses were performed 
using an ANCOVA with age and sex as covariates, followed by a Bonferroni post-hoc test. * p<0.05, 
** p<0.01, *** p<0.001 as compared to controls. Abbreviations: CTL or C: controls; Coll IV: 
collagen IV; HD or H: Huntington’s disease. . Scale bar C = 100 µm. 
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Figure 7. In vivo evidence of BBB disruption in HD patients. (A) Quantification of Gd-DTPA in the 
caudate and putamen of HD patients (n=7) and age- and sex-matched controls (n=7). (B) Brain 
map of Gd-DTPA leakage from a representative HD patient and a control, with ROI for the left and 
right caudate and putamen (white) (C) BBB permeability in the right caudate nucleus positively 
correlated with the burden of disease score in HD patients, although all regions showed a similar 
trend. Statistical analysis was performed using a paired Student’s t-test. Coefficients of 
correlation were determined using the Pearson’s correlation test; * p<0.05. Abbreviations: CTL: 
controls; HD: Huntington’s disease. 
 
Figure 8. Evidence of paracellular disruption of the BBB in the R6/2 mouse. (A-C) Transmission 
electron microscopy in the striatum of R6/2 mice (n=6) showing wider intercellular clefts of TJs 
(white arrowheads, in C) on the lumenal side (A) as well as a wider angle of TJs with respect to 
the lumen as compared to WT littermates (n=6) (B). (C) Representative transmission electron 
micrographs of a TJ in a WT and a R6/2 mouse. (D) Measurements of the expression of the TJ 
proteins claudin-5 and occludin reveal a significant decrease of both proteins in the R6/2 striatum 
(n=8) as compared to WT (n=7). (E) A greater number of CD45+ perivascular macrophages (gray) 
are associated with blood vessels (collagen IV; red) in the R6/2 mouse as compared to WT. Data 
are expressed as means ± SEM. Statistical analysis was performed using an unpaired Student’s t-
test, with a Welch correction if variances were not equal. * p<0.05 vs. controls. Abbreviations: 
Coll IV: collagen IV; DAPI: 4’, 6-diamidino-2-phenylindole; L: lumen; TJ: tight junction; WT: wild 
type. Scale bars C = 100 nm; E = 30 µm.  
  
Figure 9. Evidence for disruption of transcytosis in the R6/2 mouse. (A) Quantification of the 
mean vesicle density with increases in R6/2 mice. (B) Examples of luminal vesicle type I (red 
arrowhead), type II (white arrow), cytoplasmic (white arrowhead) and abluminal vesicles (red 
arrow) depicted by transmission electron microscopy. (C) Quantification of the different types of 
vesicles revealed an increase in total vesicles and in type II luminal vesicles in R6/2 mice. (D) mHtt 
aggregates were detected using EM48 immunogold labeling in the endothelium of R6/2 mice 
(inset 3) as well as in luminal type I (insets 1, 2 and 5), type II (inset 6), cytoplasmic (inset 8) and 
Drouin-Ouellet et al., 2015  
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abluminal vesicles (inset 4). Gold particles were also frequently found in pericytes of R6/2 mice 
(inset 7). (E) Quantification of albumin+ staining (green) reveals an increase of albumin in the 
striatal parenchyma of R6/2 mice (n=8) as compared to WT littermates (n=5). Blood vessels were 
stained using lectin-594 (red). (F) Transmission electron microscopy analysis of pericyte coverage 
did not unveil any difference between R6/2 (n=6) and WT littermates (n=6). (G) qPCR 
quantification of PDGF in the mouse striatum showed a decrease in R6/2 mice (n=10) as 
compared to WT (n=10). Data are expressed as means ± SEM. Statistical analysis was performed 
using an unpaired Student’s t-test, with a Welch correction when variances were unequal. * 
p<0.05, ** p<0.01 as compared to controls. Abbreviations: E: endothelium; L: lumen; PDGF: 
platelet-derived growth factor ; WT: wild type. Scale bars B = 100 nm; D = 200 nm; E = 100 µm. 
 
Figure 10. Schematic recapitulating findings collected both in R6/2 and HD patients as well as the 
hypothesized transport of mHtt to the brain by the transmigration of immune cells through the 
leaky BBB.   
 
 
 
Table	  1	  	  
3T	  MRI-­‐DCE	  
Patients	  
Age	   Sex	   CAG	   Disease	  duration	   UHDRS	   TFC	  
Controls	  
Age	   Sex	  
41	   M	   43	   nk	   0	   12	   27	   M	  
42	   F	   44	   nk	   13	   9	   37	   F	  
49	   M	   43	   11	   18	   5	   38	   M	  
51	   M	   43	   14.5	   3	   12	   39	   M	  
59	   F	   41	   24.5	   30	   6	   52	   M	  
66	   M	   42	   5	   12	   13	   55	   F	  
68	   M	   41	   13.5	   18	   11	   63	   M	  
	   	   	   	   	   	   	   	   	   	  
7T	  MRI	  ASL	  
Patients	  
Age	   Sex	   CAG	   Disease	  duration	   UHDRS	   TFC	  
Controls	  
Age	   Sex	  
27	   M	   nk	   6	   38	   5	   28	   M	  
51	   M	   43	   11	   18	   5	   47	   M	  
51	   M	   43	   14	   16	   11	   53	   M	  
60	   F	   41	   25	   30	   6	   54	   M	  
63	   M	   nk	   22	   32	   1	   61	   M	  
65	   M	   42	   7	   12	   13	   63	   F	  
67	   M	   41	   13	   18	   11	   64	   M	  
77	   M	   30	   10	   15	   7	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Suppl	  Table	  1	  	  	  
	  	  
ID	   GRADES	   age sex	   CAG	  repeats	   PM	  delay	  
HD	  cases	  
H689	   1	   73	   M	   nk	   nk	  
H681	   2	   64	   M	   45	   nk	  
H697	   2	   45	   M	   47	   nk	  
H704	   2	   57	   M	   43	   2.3	  
H706	   2	   66	   M	   46	   30.3	  
H711	   2	   73	   M	   45	   33	  
H721	   2	   61	   M	   46	   29	  
H630	   3	   63	   M	   46	   nk	  
H646	   3	   59	   M	   46	   73	  
H652	   3	   34	   M	   47	   nk	  
H653	   3	   65	   F	   44	   nk	  
H685	   3	   47	   M	   49	   nk	  
H688	   3	   54	   M	   47	   nk	  
H690	   3	   55	   M	   51	   26	  
H696	   3	   61	   F	   46	   nk	  
H701	   3	   51	   M	   49	   14.3	  
H712	   3	   78	   M	   43	   29	  
H714	   3	   63	   F	   46	   42.3	  
H722	   3	   73	   M	   45	   35	  
H644	   4	   51	   M	   52	   24	  
H674	   4	   53	   F	   52	   nk	  
H682	   4	   40	   M	   51	   nk	  
H683	   4	   47	   M	   52	   30	  
H684	   4	   50	   M	   50	   nk	  
H687	   4	   43	   M	   53	   nk	  
H691	   4	   65	   M	   46	   nk	  
H692	   4	   43	   F	   54	   nk	  
H693	   4	   26	   F	   70	   42.3	  
H708	   4	   44	   M	   53	   30.3	  
H710	   4	   43	   M	   51	   40.3	  
H720	   4	   68	   M	   45	   nk	  
Control	  cases	  
C515	   	  	   54	   M	   	  	   nk	  
C518	   	  	   40	   M	   	  	   nk	  
C541	   	  	   61	   F	   	  	   nk	  
C547	   	  	   72	   F	   	  	   nk	  
C557	   	  	   61	   M	   	  	   28.2	  
C566	   	  	   56	   M	   	  	   22	  
C567	   	  	   75	   M	   	  	   17	  
C568	   	  	   69	   M	   	  	   55	  
C572	   	  	   59	   M	   	  	   30	  
PT114	   	  	   63	   F	   	  	   72	  
PT34	   	  	   61	   F	   	  	   71	  
PT51	   	  	   67	   M	   	  	   14.3	  
PT56	   	  	   67	   M	   	  	   29.3	  
PT62	   	  	   78	   M	   	  	   77	  
S177	   	  	   59	   M	   	  	   nk	  
Y36	   	  	   32	   M	   	  	   nk	  
